Monitoring of bone turnover markers does not improve persistence with ibandronate treatment - 30/06/12
, Bruno Giraudeau b, c, d, Stéphanie Rouanet e, Geneviève Dubourg f, Elodie Perrodeau b, Philippe Ravaud d
Corresponding author. Tel.: +33 1 58 41 25 84; fax: +33 1 44 07 01 07.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 4 |
| Iconografia | 1 |
| Video | 0 |
| Altro | 0 |
Abstract |
Objective |
To assess if the use of biological marker of bone resorption (CTX) feedback is a mean to improve persistence on monthly oral ibandronate.
Methods |
One year prospective multicenter study using a cluster randomisation design with physicians as randomized units into two groups, A and B; in group B, physicians used results of CTX and two standardized messages according to CTX changes from baseline: suboptimal if decrease less than 30% at week 6, positive otherwise. In group A, the follow-up was standard of care. Patients were postmenopausal women, initiating a treatment with ibandronate 150mg monthly. They were blinded to the study hypotheses and outcome. The outcome was the proportion of patients persistent at 1-year visit.
Results |
Eighty-eight physicians were randomized in group A and included 346 patients, 75 in group B included 250 patients. The persistence at 1-year was high and not different between the two groups (75.1 and 74.8% P=0.932). There was no difference in the proportion of persistent patients according to the message delivered in the group of patient with CTX information: 77.4 and 74.8% in patients with a suboptimal or positive message respectively.
Conclusion |
This study failed to demonstrate that supporting monitoring of CTX could improve persistence to ibandronate treatment in postmenopausal osteoporosis.
Key messages |
Persistence is a strong determinant of anti-osteoporotic treatments efficacy. Monitoring of bone markers is not a mean to improve persistence of an oral bisphosphonate. There is a discrepancy between levels of persistence in clinical studies and real life.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Osteoporosis, Persistence, Bone turnover markers, Cluster randomisation
Mappa
Vol 79 - N° 4
P. 389-392 - luglio 2012 Ritorno al numero
Articolo precedente
- Reproducibility and influence of hand rotation on computer-aided joint space analysis
- Alexander Pfeil, Andreas Hansch, Julia Sommerfeld, Rosemarie Fröber, Diane M. Renz, Gabriele Lehmann, Ansgar Malich, Gunter Wolf, Joachim Böttcher
- Epidemiogenetic study of French families with Paget’s disease of bone
- Laëtitia Michou, Corinne Collet, Jean Morissette, Maurice Audran, Thierry Thomas, Edith Gagnon, Jean-Marie Launay, Jean-Louis Laplanche, Jacques P. Brown, Philippe Orcel
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?